Novo Nordisk AS
NVO
Company Profile
Business description
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Contact
Novo Alle 1
Bagsvaerd2880
DNKT: +45 44448888
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
72,000
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,789.70 | 43.80 | 0.50% |
CAC 40 | 7,950.17 | 8.53 | 0.11% |
DAX 40 | 21,732.05 | 4.85 | 0.02% |
Dow JONES (US) | 44,544.66 | 337.47 | -0.75% |
FTSE 100 | 8,673.96 | 27.08 | 0.31% |
HKSE | 20,225.11 | 27.34 | 0.14% |
NASDAQ | 19,627.44 | 54.31 | -0.28% |
Nikkei 225 | 39,572.49 | 58.52 | 0.15% |
NZX 50 Index | 12,995.01 | 66.63 | 0.52% |
S&P 500 | 6,040.53 | 30.64 | -0.50% |
S&P/ASX 200 | 8,532.30 | 38.60 | 0.45% |
SSE Composite Index | 3,250.60 | 2.03 | -0.06% |